Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy

Pharmacogenomics

Volumn 14, Issue 8, 2013, Pages 941-956

  Angelini, Sabrina ^a   Ravegnini, Gloria ^a,b   Fletcher, Jonathan A ^b   Maffei, Francesca ^a   Hrelia, Patrizia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

gastrointestinal stromal tumor; imatinib; imatinib pharmacokinetics; KIT mutations; PDGFRA mutations; plasma level

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AT 13387; BIIB 021; BIIB 022; CRENOLANIB; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DASATINIB; EVEROLIMUS; GANETESPIB; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IMG 3G3; LUMINESPIB; MASITINIB; NILOTINIB; OLARATUMAB; PAZOPANIB; PERIFOSINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RAPAMYCIN; REGORAFENIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL TIME;

BENZAMIDES; DRUG MONITORING; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84878833216     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.63     Document Type: Review

References (123)

1. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103(4), 821-829 (2005). (Pubitemid 40216412)
2. Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int. J. Cancer 117(2), 289-293 (2005). (Pubitemid 41377450)
3. Chan KH, Chan CW, Chow WH et al. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J. Gastroenterol. 12(14), 2223-2228 (2006).
4. Benesch M, Leuschner I, Wardelmann E et al. Gastrointestinal stromal tumours in children and young adults: a clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS). Eur. J. Cancer 47(11), 1692-1698 (2011).
5. Stiller CA, Trama A, Serraino D et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur. J. Cancer 49(3), 684-695 (2013).
6. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 369(9574), 1731-1741 (2007). (Pubitemid 46778870)
7. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22, 3813-3825 (2004). (Pubitemid 41095223)
8. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472-480 (2002). (Pubitemid 34879334)
9. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440), 1127-1134 (2004). (Pubitemid 39296599)
10. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutation in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23(23), 5357-5364 (2005). (Pubitemid 46206989)
11. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26(4), 626-632 (2008). (Pubitemid 351264358)
12. Benesch M, Leuschner I, Wardelmann et al. Gastrointestinal stromal tumors (GIST) in children and adolescents: a comprehensive review of the current literature. Pediatr. Blood Cancer 53(6), 1171-1179 (2009).
13. Miettinen M, Sobin LH, Lasota J et al. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am. J. Surg. Pathol. 29(1), 52-68 (2005). (Pubitemid 40023952)
14. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350), 577-580 (1998). (Pubitemid 28067289)
15. Heinrich MC, Corless CL, Demetri GD et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607), 708-710 (2003). (Pubitemid 36159485)
16. Hirota S, Ohashi A, Nishida T et al. Gain-of-function mutations of platelet-derived growth factor receptor agene in gastrointestinal stromal tumors. Gastroenterology 125(3), 660-667 (2003). (Pubitemid 37070684)
17. Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur. J. Cancer 39(14), 2006-2011 (2003). (Pubitemid 37297756)
18. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized Phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26(4), 620-625 (2008). (Pubitemid 351264357)
19. van Glabbeke M, Verweij J, Casali PG et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for research and treatment of Cancer-Italian Sarcoma Group-Australasian gastrointestinal trials group study. J. Clin. Oncol. 23(24), 5795-5804 (2005).
20. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544), 1329-1338 (2006). (Pubitemid 44528723)
21. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 23(2), 70-83 (2006). (Pubitemid 44692418)
22. Ylipää A, Hunt KK, Yang J et al. Integrative genomic characterization and genomic staging system for gastrointestinal stromal tumors. Cancer 117(2), 380-389 (2011).
23. Agaimy A, Terracciano LM, Dirhofer S et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J. Clin. Pathol. 62(7), 613-616 (2009).
24. Hostein I, Faur N, Primois C et al. BRAF mutation status in gastrointestinal stromal tumors. Am. J. Clin. Pathol. 133(1), 141-148 (2010).
25. Miranda C, Nucifora M, Molinari F et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin. Cancer Res. 18(6), 1769-1776 (2012).
26. Kinoshita K, Hirota S, Isozaki K et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J. Pathol. 202(1), 80-85 (2004). (Pubitemid 38072848)
27. Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am. J. Surg. Pathol. 29(9), 1170-1176 (2005). (Pubitemid 41232989)
28. Janeway KA, Kim SY, Lodish M et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc. Natl Acad. Sci. USA 108(1), 314-318 (2011).
29. Oudijk L, Gaal J, Korpershoek E et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod. Pathol. 26(3), 456-463 (2013).
30. Antonescu CR, Viale A, Sarran L et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin. Cancer Res. 10(10), 3282-3290 (2004). (Pubitemid 38685432)
31. Tarn C, Rink L, Merkel E et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc. Natl Acad. Sci. USA 105(24), 8387-8392 (2008). (Pubitemid 351904765)
32. Pantaleo MA, Astolfi A, Di Battista M et al. Insulin-like growth factor 1 receptor (IGF1r) expression in wild-type GISTs: a potential novel therapeutic target. Int. J. Cancer 125(12), 2991-2994 (2009).
33. Plaat BE, Hollema H, Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J. Clin. Oncol. 18(18), 3211-3220 (2000).
34. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after Sti-571. Hum. Pathol. 33(5), 466-477 (2002). (Pubitemid 34747865)
35. Trent JC, Beach J, Burgess MA et al. A two-arm Phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 98(12), 2693-2699 (2003). (Pubitemid 37509535)
36. Patel S. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treat. Rev. 38(5), 467-472 (2012).
37. Raut CP, Ashley SW. How I do it: surgical management of gastrointestinal stromal tumors. J. Gastrointest. Surg. 12(9), 1592-1599 (2008).
38. Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update on the NCCN clinical practice guidelines. J. Natl Compr. Canc. Netw. (Suppl. 2), S1-S29 (2007).
39. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet 358(9291), 1421-1423 (2001). (Pubitemid 33055745)
40. Demetri GD, von Mehren M, Antonescu CR et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J. Natl. Compr. Canc. Netw. (Suppl. 2), S1-S41 (2010).
41. Choi H, Charnsangavej C, Faria S et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25(13), 1753-1759 (2007). (Pubitemid 46797957)
42. Jjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J. Clin. Oncol. 25(13), 1760-1764 (2007). (Pubitemid 46797958)
43. Sevinc A, Turhal NS. 'Please, desist RECIST criteria in GIST, at least in me'. Onkologie 31, 556 (2008).
44. Eisenberg BL, Harris J, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J. Surg. Oncol. 99(1), 42-47 (2009).
45. McAuliffe JC, Hunt KK, Lazar AJ et al. A randomized, Phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann. Surg. Oncol. 16(4), 910-919 (2009).
46. Blesius A, Cassier PA, Bertucci F et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 11, 72 (2011).
47. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, on behalf of the ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO Clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), S64-S67 (2009).
48. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo controlled trial. Lancet 373(9669), 1097-1104 (2009).
49. Li J, Gong JF, Wu AW, Shen L. Postoperative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur. J. Surg. Oncol. 37(4), 319-324 (2011).
50. Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12), 1265-1272 (2012).
51. Bilimoria KY, Wayne JD, Merkow RP et al. Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States. Ann. Surg. Oncol. 19(1), 184-191 (2012).
52. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer 11(12), 865-878 (2011).
53. Sawaki A, Nishida T, Yamada Y et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117(20), 4633-4641 (2011).
54. Park SH, Ryu MH, Ryoo BY et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a Phase II study of Korean gastrointestinal stromal tumors study group. Invest. New Drugs 30(6), 2377-2383 (2012).
55. Demetri GD, Lo Russo P, MacPherson IR et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin. Cancer Res. 15(19), 6232-6240 (2009).
56. George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicentre Phase II trial. J. Clin. Oncol. 30(19), 2401-2407 (2012).
57. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicentre, randomized, placebo-controlled, Phase 3 trial. Lancet 381(9863), 295-302 (2013).
58. Le Cesne A, Blay JY, Bui BN et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST). Eur. J. Cancer 46(8), 1344-1351 (2010).
59. Joensuu H, De Braud F, Grignani G et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a Phase II study. Br. J. Cancer 104(11), 1686-1690 (2011).
60. Schöffski P, Reichardt P, Blay JY et al. A Phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann. Oncol. 21(10), 1990-1998 (2010).
61. Lamba G, Ambrale S, Lee B et al. Recent advances and novel agents for gastrointestinal stromal tumor. J. Hematol. Oncol. 5, 21 (2012).
62. Dickson MA, Okuno SH, Keohan ML et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann. Oncol. 24(1), 252-257 (2013).
63. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003). (Pubitemid 46621810)
64. Debiec-Rychter M, Dumez H, Judson I et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on Phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 40(5), 689-695 (2004). (Pubitemid 38326618)
65. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42(8), 1093-1103 (2006). (Pubitemid 44275331)
66. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group. J. Clin. Oncol. 26(33), 5360-5367 (2008).
67. Yeh CN, Chen YY, Tseng JH et al. Imatinib mesylate for patients with recurrent or metastatic gastrointestinal stromal tumors expressing KIT: a decade experience from Taiwan. Transl. Oncol. 4(6), 328-335 (2011).
68. Kang HJ, Ryu MH, Kim KM et al. Imatinib efficacy by tumor genotypes in Korean patients with advanced gastrointestinal stromal tumors (GIST): the Korean GIST Study Group (KGSG) study. Acta Oncol. 51(4), 528-536 (2012).
69. Gao Y, Dang Y, Sun N, Li J, Shen L. C-KIT mutations were closely associated with the response to imatinib in Chinese advanced gastrointestinal stromal tumor patients. Med. Oncol. 29(5), 3039-3045 (2012).
70. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J. Clin. Oncol. 28(7), 1247-1253 (2010).
71. Rössle M, Hirschmann A, Diebold J. Mutational spectrum and therapy response of metastasized GIST in central Switzerland-a population-based study. Eur. J. Cancer 47(9), 1305-1311 (2011).
72. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 26(33), 5352-5359 (2008).
73. Weisberg E, Wright RD, Jiang J et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 131(6), 1734-1742 (2006). (Pubitemid 44958515)
74. Cassier PA, Fumagalli E, Rutkowski P et al. Outcome of patients with plateled-derived growth factor receptor a-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin. Cancer Res. 18(16), 4458-4464 (2012).
75. Chen LL, Trent JC, Wu EF et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 64(17), 5913-5919 (2004). (Pubitemid 39129383)
76. Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutations. Clin. Cancer Res. 11(11), 4182-4190 (2005). (Pubitemid 40791584)
77. Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur. J. Cancer 41(12), 1751-1757 (2005). (Pubitemid 41132637)
78. Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24(29), 4764-4777 (2006).
79. Yoon DH, Ryu MH, Ryoo BY et al. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Invest. New Drugs 30(2), 819-827 (2012).
80. Rutkowski P, Bylina E, Klimczak A et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure-one institution study. BMC Cancer 12, 107 (2012).
81. Reynoso D, Trent JC. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. Curr. Opin. Oncol. 22(4), 330-335 (2010).
82. Gronchi A. Risk stratification models and mutational analysis: keys to optimizing adjuvant therapy in patients with gastrointestinal stromal tumor. Eur. J. Cancer 49(4), 884-892 (2013).
83. von Mehren M, Benjamin RS, Bui MM et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J. Natl Compr. Canc. Netw. 10(8), 951-960 (2012).
84. Merkelbach-Bruse S, Dietmaier W, Füzesi L et al. Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. BMC Med. Genet. 11, 106 (2010).
85. Hostein I, Debiec-Rychter M, Olschwang S et al. A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours. J. Gastroenterol. 46(5), 586-594 (2011).
86. Wong NA, Dean ZC, Ramsden SC. The UK NEQAS for molecular genetics scheme for gastrointestinal stromal tumour: findings and recommendation following four rounds of circulation. J. Clin. Pathol. 65(9), 786-790 (2012).
87. Wanderlmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutatons in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res. 12(6), 1743-1749 (2006).
88. Wang WL, Conley A, Reynoso D et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother. Pharmacol. 67(Suppl. 1), S15-S24 (2011).
89. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin. Cancer Res. 15(24), 7510-7518 (2009).
90. Demetri GD, Wang Y, Wehrle E et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J. Clin. Oncol. 27(19), 3141-3147 (2009).
91. Widmer N, Decosterd LA, Leywraz S et al. Relationship of imatinib free plasma levels and target genotype with efficacy and tolerability. Br. J. Cancer 98(10), 1633-1640 (2008). (Pubitemid 351684684)
92. Judson I, Peiming M, Peng B et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 55(4), 379-386 (2005). (Pubitemid 40379262)
93. Delbaldo C, Chatelut E, Ré M et al. Pharmacokinetic- pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin. Cancer Res. 12(20), 6073-6078 (2006). (Pubitemid 44703771)
94. von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat. Rev. 37(4), 291-299 (2011).
95. Eechoute K, Fransson MN, Reyners AK et al. Imatinib plasma concentrations in GIST patients. Clin. Cancer Res. 18(20), 5780-5787 (2012).
96. Bolton AE, Peng B, Hubert M et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother. Pharmacol. 53(2), 102-106 (2004). (Pubitemid 38186987)
97. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21(8), 1637-1647 (2003). (Pubitemid 46594119)
98. Takahashi N, Miura M, Scott SA et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic myeloid leukemia. J. Hum. Genet. 55(11), 731-737 (2010).
99. Singh O, Chan JY, Lin K, Heng CC, Chowbay B. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS ONE 7(12), e51771 (2012).
100. Dulucq S, Bouchet S, Turcq B et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112(5), 2024-2027 (2008).
101. Kim DH, Sriharsha L, Xu W et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res. 15(14), 4750-4758 (2009).
102. Ni LN, Li JY, Miao KR et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med. Oncol. 28(1), 265-269 (2011).
103. Angelini S, Soverini S, Ravegnini G et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 98(2), 193-200 (2013).
104. Angelini S, Pantaleo MA, Ravegnini G et al. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumors treated with imatinib therapy. Pharmacol. Res. 68(1), 1-6 (2013).
105. Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8(5), 935-942 (2002). (Pubitemid 34520420)
106. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther. 76(4), 323-329 (2004). (Pubitemid 39313122)
107. Amirimani B, Ning B, Deits AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4 1B promoter variant. Environ. Mol. Mutagen. 42(4), 299-305 (2003). (Pubitemid 38054375)
108. Peng B, Hayes M, Resta D et al. Pharmacokinetics and pharmacodynamics of imatinib in a Phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22(5), 935-942 (2004). (Pubitemid 41103606)
109. Gréen H, Skoglund K, Rommel F, Mirghani RA, Lotfi K. Cyp3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur. J. Clin. Pharmacol. 66(4), 383-396 (2010).
110. Filpulla AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab. Dispos. 41(1), 50-59 (2013).
111. Pander J, Guchelaar HJ, Gelderblom H. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: optimizing the magic bullet. Curr. Opin. Mol. Ther. 12(6), 654-661 (2010).
112. Le Cesne A, Ray-Coquard I, Bui BN et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicenter randomized Phase 3 trial. Lancet Oncol. 11(10), 942-949 (2010).
113. Patrikidou A, Chabaud S, Ray-Coquard I et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomized, Phase III trial. Ann. Oncol. 24(4), 1087-1093 (2013).
114. Mazzeo F, Duck L, Joosens E et al. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res. 31(4), 1407-1409 (2011).
115. Montemurro M, Gelderblom H, Bitz U et al. Sorafenib as third-or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: a retrospective analysis. Eur. J. Cancer 49(5), 1027-1031 (2013).
116. Subramanian S, West RB, Corless CL et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 23(47), 7780-7790 (2004). (Pubitemid 39457028)
117. Kang HJ, Nam SW, Kim H et al. Correlation of KIT and platelet-derived growth factor receptor amutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24(6), 1066-1074 (2005). (Pubitemid 40313883)
118. Birner P, Beer A, Vinatzer U et al. MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clin. Cancer Res. 18(7), 1879-1887 (2012).
119. Rink L, Skorobogatko Y, Kossenkov A et al. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol. Cancer Ther. 8(8), 2172-2182 (2009).
120. Kim WK, Park M, Kim YK et al. MicroRNA-494 downregulates kit and inhibits gastrointestinal stromal tumor cell proliferation. Clin. Cancer Res. 17(24), 7584-7594 (2011).
121. Koelz M, Lense J, Wrba F, Scheffler M, Dienes HP, Odenthal M. Down-regulation of miR-221 and miR-222 correlates with pronounced kit expresion in gastrointestinal stromal tumors. Int. J. Oncol. 38(2), 503-511 (2011).
122. Eechoute K, Sparreboom A, Burger H et al. Drug transporters and imatinib treatment: implication for clinical practice. Clin. Cancer Res. 17(3), 406-415 (2011).
123. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11(1), 89-103 (2010).